Big Pharma's hunting the generics.......................

Big pharma daddy's pipeline is drying up in the coming decades and beacuse of generic competion many large pharmaceuticals are loosing into their profit margins, so the stratergy both GSK and Pfizer are following is that they atr activeky hunting out for good profitable generic companies in the emerging market.

for sometime around GSK has been making headlines with many smaller and medium size generic and bio similar acquisition and now pfizer is rolling uo its sleeves and has started its stratergia acquisitions in the emerging markets such as Turkey in Middle east. Some reports have stated that Pfizer has announced that it wants to have generic drugs revenue to be more than 3 Biollion by year 2012.

Nycomed Big Move .................................

Nycomed is going for a big move it is planning to acquire Solvay pharmaceutical, this deal will boost Nycomed sales to more than $9 Billion and will help Nycomed to diversify their portfolio in gastrointestinal, CNS, and cardiac areas.

Nycomed after this deal can penetrate its operations in Europe and in the emerging markets such as India. Some reports say that Nycomed which is controlled by Nordic Capital and Credit Suisse Group AG is interested in selling its shares with Initial public offering later this year as IPO will help them to repay their investors and this deal will also help them move into league of bigger and diversified pharmaceutical company.

Japanese pharma on M&A move ............................

After Ranbaxy was acquired by Daichii Sankyo last year than this year again at perhaps same time another Japanese company Hisamitsu Pharmaceutical bought Miami-based Noven Pharmaceutical for $430 million. Hisamitsu Pharmaceutical is interested in expanding in the U.S., Hisamitsu agreed to pay $16.50 a share, a 38 percent premium on the company's 50-day close. Hisamitsu plans to make the company with specialization in hormone therapies to be a wholly-owned subsidiary of the Japanese firm, Today’s headline is that one more Japanese firm and Nycomed are in the early second round of an auction for all of Solvay's pharmaceuticals business.....this time we have Japanese in race with US and UK based companies in global M&A.

US Senate vote........for Biologicals

As mentioned by me in my earlier blog that Senator Ted kennedy wanted 13.5 years of IP protection for biological, everyone was waiting for this amendment. Yesterday the US senate Health, Education, Labour and Pensions Committee approved an amendment that will be protecting biotech innovator companies from bio similar competition for 12 years. The voting favoured--the biotech industry with a big win which was struggling to gain a long period of marketing protection.

The 12 years of data exclusivity will establish reasonable period and will ensure continuation of biomedical innovation and will provide the benefits of competition," said BIO President Jim Greenwood.

Strides Lab into M&A Activity..........

Strides labs(Bangalore) which is into manufacturing of sterile injectables and oral dosage formulations with global presence in Latin America, Africa, US, Southeast Asia and also has several manufacturing facilities overseas is interested in selling stakes of its branded-generics pharmaceutical company.

Potential investors may think of investing in the specialty pharma unit, which is focused on manufacturing of sterile injectables as one report states that the global injectable market is estimated to grow from USD 150 billion in year 2008 to USD 245 billion by 2012.

Recession again from back door..............................

Last weekend i had been for a small trip to Jaipur (Pink city of India), In the heart of the city near the choti chowpad area i saw a temple in which in front it was written temmple for "God of employment",I was surprised and then thought, Probably what we are expecting about good times to happen soon is not going to happen, it will take one year more for things to settle, As of now for the past one month i am hearing that people are made to quit there job all over US and things are likewise happening in india too :(

Last week majour surprise came from genetech end and in India many small companies are asking people to work without pay.....

I think we all have to watch and pray to "God of employement" so that people jobs are safe and secured till the next recession cycle which is going to happen soon :(

Cadila's New Venture .......................

Cadila Pharmaceuticals (India) yesterday announced that it is venturing With Novavax, Inc (United States). The new venture will be called as CPL Biologicals Pvt. Ltd, this company will focus into development, production of vaccines by using one of its own kind cutting-edge vaccine technology and will sell products like seasonal influenza vaccine, novel vaccines against dengue fever and chikungunya fever based on Novavax's virus-like-particle (VLP) vaccine technology and also will try to develop pandemic H1N1 influenza vaccine in India which Novavax is developing in United States.

The company will thus join the league of vaccine production companies such as Serum institute of India and Bharat Immunological which are already provider for high quality affordable vaccines, therapeutics and diagnostics by carrying out world-class research and innovative manufacturing process for current global health challenges.

New Biopharmaceutical Exclusivity Proposal……………….

For sometime there has been hue and cry from biopharmaceutical companies in United States regarding the extension of period of exclusivity for Biopharmaceutical drugs from 12 years to 14 years, this exclusivity will not only help these companies to protect them from Biosimilar drugs competition but will also give theses companies time to invest on development of new medicines.

Yesterday there was news that a senior democrat Mr. Edward Kennedy, chairman of the Senate health committee, in United States proposed an extension of 13.5 years for these biopharmaceuticals drugs for their protection from biosimilar competition.

Under this proposal Biopharmaceuticals will be receiving nine years of protection, plus up to four-and-a-half additional years for new uses or pediatric studies.